BUZZ-Beam Therapeutics rises after gene-editing drug shows promise in rare lung and liver disease
Reuters03-25 19:27
BUZZ-Beam <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises after gene-editing drug shows promise in rare lung and liver disease
** Shares of biotech firm Beam Therapeutics BEAM.O rise 12% to $27.01 premarket
** Co says its experimental gene‑editing drug BEAM‑302 showed promising results in an early‑stage study for alpha‑1 antitrypsin deficiency, a rare inherited condition that can damage the lungs and liver
** Says a single 60‑mg dose kept patients above healthy levels of a protective lung protein for up to 12 months and sharply cut a harmful mutant protein
** Drug was well tolerated, with mild to moderate side effects and no serious safety issues seen in 29 patients – BEAM
** Co says it plans a late‑stage study in the second half of 2026; U.S. FDA may consider accelerated approval based on biomarker data
** Shares up ~12% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments